Brainlab to become distributor of Elekta's stereotactic neurosurgery products in US

Elekta's Leksell Vantage Stereotactic System

December 15, 2017
by Lauren Dubinsky , Senior Reporter
Elekta announced on Wednesday that Brainlab will be the exclusive distributor for its stereotactic neurosurgery products in the U.S.

The Munich-based company is already the distributor of these products in select European markets.

The agreement includes the Leksell Vantage Stereotactic System, which is Elekta's next-generation system for target localization and coordinate referencing for neurosurgical procedures.

It scored CE mark in March and has already been adopted by neurosurgeons in Europe. The system also recently received FDA clearance and is commercially available in the U.S.

In September 2016, Elekta and Brainlab started working together on integrating the Leksell Vantage and Brainlab's Elements Stereotaxy treatment planning and verification software. The combined use of both technologies is intended to make stereotactic neurosurgical procedures safer.

Elekta specifically chose Brainlab as the distributor of these products in the U.S. due to the company's large and specialized sales and service team.

The company, which was founded in 1989, has about 1,300 employees and operates 18 offices across Europe, Asia, Australia and North and South America.

It started as a software company with solutions ranging from patient positioning for radiosurgery to software-guided surgical navigation, and it has evolved to develop hardware systems.

"By partnering with Elekta, we are increasing our reach and providing clinicians with advanced and innovative technology on the stereotactic neurosurgery market," Paolo Jelmoni, VP of functional and stereotactic neurosurgery at Brainlab, said in a statement.

More Business Affairs

Varian acquires Noona Healthcare

Philly leads US cities in need of radiologists

Siemens Healthineers holds grand opening of new Erlangen HQ

Does GE CEO move cast doubt on healthcare spinoff?

Healthcare has a serious problem with wasted spending

Mass imaging exam cancellations by VA puts veterans lives at risk

Hologic to acquire Focal Therapeutics for $125 million

GE CEO Flannery is out as Culp Jr. named chairman and CEO

China tariffs now hit $4.7 billion worth of U.S. medical devices

Samsung in talks with Nipro for medical device division sale